Literature DB >> 6245189

Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex.

P Guiheneuc, J Ginet, J Y Groleau, J Rojouan.   

Abstract

Ten patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface during the first week of each month for 3 months). The motor conduction velocity of the peroneal nerve, the conduction velocity in palmar sensory fibres of the median nerve, and the conduction velocity in the H reflex pathway remained unchanged. The amplitude of distal muscle (extensor digitorum brevis) and sensory nerve (median) potentials decreased, while the maximal response of more proximal muscles (soleus) was not significantly modified. The soleus T response quickly decreased, although at the same time the H response was increased in the days following administration of vincristine. Thus the T/H ratio seems to be the only convenient electrophysiological method of evaluating the functional impairment of primary afferent distal segments. These results show that vincristine induces a transitory excitability enhancement of the monosynaptic reflex. It is suggested that the drug may cause an increase in the firing rate in proximal segments of injured Ia fibres. Apart from this phenomenon the electrophysiological results lead to the conclusion that vincristine induces distal axonal degeneration, similar to that in other toxic neuropathies (e.g. acrylamide or n-hexane) where a dying-back process has been clearly demonstrated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245189     DOI: 10.1016/0022-510x(80)90179-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Spatiotemporal localization of injury potentials in DRG neurons during vincristine-induced axonal degeneration.

Authors:  Surendra K Ravula; Min S Wang; Maxine A McClain; Seneshaw A Asress; Bruno Frazier; Jonathan D Glass
Journal:  Neurosci Lett       Date:  2007-01-10       Impact factor: 3.046

2.  Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.

Authors:  Stefanie Geisler; Ryan A Doan; Amy Strickland; Xin Huang; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Brain       Date:  2016-10-25       Impact factor: 13.501

3.  Efficacy of ganglioside treatment in reducing functional alterations induced by vincristine in rabbit peripheral nerves.

Authors:  F Di Gregorio; G Favaro; C Panozzo; M G Fiori
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Neurotoxicology of vincristine in the cat. Electrophysiological studies.

Authors:  B D Goldstein; H E Lowndes; E Cho
Journal:  Arch Toxicol       Date:  1981-11       Impact factor: 5.153

5.  Comparative Analysis of Chemotherapy-Induced Peripheral Neuropathy in Bioengineered Sensory Nerve Tissue Distinguishes Mechanistic Differences in Early-Stage Vincristine-, Cisplatin-, and Paclitaxel-Induced Nerve Damage.

Authors:  Kevin J Pollard; Brad Bolon; Michael J Moore
Journal:  Toxicol Sci       Date:  2021-02-26       Impact factor: 4.849

6.  Guillain-Barre syndrome in acute lymphoblastic leukemia: Causal or coincidental.

Authors:  Bharat Bhushan; Amita Bhargava; Gaurav M Kasundra; Khichar Shubhakaran; Isha Sood
Journal:  J Pediatr Neurosci       Date:  2015 Jan-Mar

7.  Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

Authors:  Marie Lindhard Madsen; Hanne Due; Niels Ejskjær; Paw Jensen; Jakob Madsen; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-18       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.